

Special Issue

Natural Products for Potential Use of Neuroprotective and Neurorestorative Effects in Stroke

Message from the Guest Editors

In this Special Issue, we aim to provide the most recent updates on natural product research for treating stroke involving both the nervous system and immune system, which will include in vitro, in vivo and clinical studies. Both original and review articles are welcome. Manuscripts addressing the following issues are of particular interest:

- Mechanistic studies of natural product treatments for protecting against ischemic stroke injury by targeting the central nervous system and/or immune system;
- Mechanistic studies of natural product treatments for promoting post-stroke brain recovery via modulating neuronal damages and/or CNS/peripheral immune responses such as inhibiting neurodegeneration, neuroinflammation and peripheral immune suppression and promoting neurogenesis;
- Investigation of natural compounds in stroke models that account for comorbidity, such as hyperglycemia, hypertension and hyperlipidemia;
- Adjunct therapy of natural products with current therapy for stroke treatment;
- Potential combination therapy of natural products with other potential treatments, such as stem cells and optogenetic stimulation.

Guest Editors

Dr. Hansen Chen

Department of Neurosurgery, School of Medicine, Stanford University, Stanford, CA, USA

Dr. Qingkun Liu

Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Deadline for manuscript submissions

closed (30 June 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed



mdpi.com/si/127583

Pharmaceuticals
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)